This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Majority Of Medical Oncologists And Ob-Gyns Disagree With New Mammogram Recommendations, New Infogroup’s ORC Oncology Report Indicates

Recent recommendations by the US Preventive Task Force on Breast Cancer advising that women under the age of 50 should not get routine mammograms have resulted in fierce debate within the medical community. According to a new oncology study from ORC, an Infogroup Company, 70 percent of oncologists and 60 percent of ob-gyns disagree with the assertion that women should not get mammograms before the age of 50. The prevailing argument against the Task Force’s mammogram recommendation is that too many women under the age of 50 have breast cancer and that it would allow many breast cancer cases to go undetected.

ORC’s Oncology Report delved into research analysis on three important Oncology issues: assessing the impact of revised NSCLC staging, genetically linked breast cancer and PARP-1 Inhibitors and Reactions to New Mammogram Recommendations. The mammogram debate was one of a number of key issues covered in ORC’s study, which captured the awareness, perceptions, ideal patient profiles and adoption rates of physicians towards PARP-1 Inhibitors post FDA-approval as a treatment for breast and ovarian cancers. PARP-1 Inhibitors have been widely discussed and exhibit efficacy in clinical trials, but minimal data has been collected so far to gauge their wider acceptance. Fifty percent of medical oncologists and 80 percent of ob-gyns were unable to name any PARP-1 inhibitor without being prompted.

“We were initially concerned with the physician’s lack of awareness and information on PARP-1 Inhibitors, since such awareness can help determine therapy and answer important questions about genetically linked breast and ovarian cancer treatment,” said Vaibhav Varkhedkar, Vice President of ORC’s Oncology Practice . “However, based on our data, we are optimistic that the usage of PARP-1 Inhibitors post FDA-approval will grow and eventually become the treatment of choice for certain hard to treat breast and ovarian cancers.”

To learn more and to obtain a copy of the full report, visit http://lp.infogroup.com/oncology-report.

About our Global Oncology Practice

As a dedicated practice within our pharmaceutical business unit, ORC’s oncology team is a well recognized and respected provider of market research solutions spanning a myriad of complex issues in cancer diagnostics and treatment. All of our oncology-based research is anchored in our extensive knowledge of latest cancer epidemiology, disease modalities and marketing implications.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG
AAPL $131.39 0.00%
FB $80.48 0.00%
GOOG $542.51 0.00%
TSLA $245.62 0.00%
YHOO $43.68 0.00%

Markets

DOW 18,285.74 +0.34 0.00%
S&P 500 2,130.82 +4.97 0.23%
NASDAQ 5,090.7940 +19.0510 0.38%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs